ABSTRACT

Objective:

Bisphosphonates are drugs that are effectively used for treating osteoporosis. Zoledronic acid (ZA) is a bisphosphonate type drug containing the imidazole group, used for treating osteoporosis. In addition to its use for treating osteoporosis, it is thought to have an anticancer effect on cancer cells, and studies have shown that ZA can also be used for treating nervous system diseases such as Alzheimer’s and Huntington’s, based on its mechanism of action. Aim this study was to investigate the effect of ZA on cytotoxicity and oxidative stress in SH-SY5Y cells.

Materials and Methods:

For cytotoxicity analysis, ZA 25, 50, 100, 200, 400, 600, 800 and 1000 μM concentrations were exposed to SH-SY5Y cells for 24 h and cytotoxicity assessment was performed using 3-[4.5-dimethylthiazol-2-yl]-2.5 diphenyl tetrazolium bromide (MTT) test. Total oxidant status (TOS) and total antioxidant status (TAS) ELISA tests were applied to oxidative stress analysis. The oxidative stress index (OSI) was calculated.

Results:

The IC50 value of ZA was calculated as 615.996 μM and the IC30 value was calculated as 466.275 μM. No statistically significant difference was observed between the groups in terms of TAS, TOS and OSI values.

Conclusion:

ZA exposure did not induce oxidative stress in SH-SY5Y cells and its cytotoxic concentrations appear as high values. For this reason, it can be considered an effective treatment option in nervous system diseases without damaging the cells. However, in vivo studies that evaluate detailed molecular mechanisms are required.